)
Sohini Das writes on automobile and healthcare sectors for Business Standard. Over her 17 years as a journalist, she has covered multiple sectors and issues -- FMCG, dairy, tourism, and state elections, among others, across Kolkata, Ahmedabad, and Mumbai. She loves doing personality stories and ground reportage.
Sohini Das writes on automobile and healthcare sectors for Business Standard. Over her 17 years as a journalist, she has covered multiple sectors and issues -- FMCG, dairy, tourism, and state elections, among others, across Kolkata, Ahmedabad, and Mumbai. She loves doing personality stories and ground reportage.
Doctors are now shifting treatment protocol for Covid-19 at hospitals and invasive ventilation is not being preferred
Other vaccine makers, such as Hyderabad-based Biological E, too, have started working on different strains.
The restricted emergency use allowed by the regulator was based on phase 2 safety and immunogenicity studies, as well as data from monkey trials
Bharat Bio says keen to follow, have capacity of 40 mn doses a month
The absence of drugs to target the Sars-CoV-2 virus had triggered research on repurposed drugs, as well as biologics
A month on, 21 states and UTs have not administered a single shot of the vaccine
After audit of Pune plant, Serum may supply vaccines to UK as well
Bharat Bio may add 200 mn doses if needed; Serum to have 2.5 mn capacity by year-end
Public vaccination back-end technology in place, private sector role likely in procuring doses for staff
Low turnout for vaccination so far a likely reason
In the interim efficacy analysis, data from 19,866 volunteers were included
Ocugen, a Nasdaq-listed firm, focuses on developing and commercialising gene therapies to cure blindness diseases
Allocation jumps 118% over RE to Rs 2.23 trillion; Rs 35,000 cr earmarked for Covid vaccination
New central scheme called Atmanirbhar Swasth Bharat Yojana gets Rs 64,180 crore in Sitharaman's budget
The company has now decided to focus on specialty drugs. The annual price cuts made the Japanese generics market unattractive
The total revenue from operations came in at Rs 5,169 crore and the net profit stood at Rs 748 crore, up 113 per cent.
The company has repaid debt of about $490 million in 9MFY21; filings for 90 ANDAs await US FDA approval
DRL said the Q3 results were impacted primarily due the non-recognition of deferred tax assets on impairment.
The bridge trials on 1,600 participants in India was ongoing. The phase 2 trials are completed and the phase 3 is on.
The trial has assessed its efficacy during a period with high transmission and with a new UK strain of the virus